JGJan Willem. B. de Groot

Jan Willem. B. de Groot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jan Willem. B. de Groot has a total of 202 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Beyond Infusion: Real-World Insights Into Infusion-Related Reactions in Monoclonal Antibody Therapy

    by Elise J. Smolders, Elianne C.S. de Boer, Helle-Brit Fiebrich-Westra, Remco van der Galiën, Peter M.J. Plomp, Jan Willem B. de Groot, Jan Gerard Maring

    PURPOSE: The exact mechanism responsible for infusion-related reactions (IRRs) after monoclonal antibody (mAb) therapy is unclear. It is also unknown before treatment which patient will develop IRRs. The reported incidence of IRRs varies per and between mAbs, and real-world incidence data are scarce. The purpose of this study was to evaluate the real-world incidence of IRRs in our large tertiary teaching hospital. METHODS: We conducted a retrospective analysis of all patients treated with at least one of the following mAbs: atezolizumab, bevacizumab, durvalumab, ipilimumab, nivolumab, panitumumab, pembrolizumab, trastuzumab, pertuzumab, and rituximab. Patient data were included between January 01, 2021, and June 30, 2022. IRRs were graded according to Common Terminology Criteria for Adverse Events. RESULTS: We included 692 patients, of whom 6.7% (n = 47) had experienced one or more IRRs (n = 63). The highest incidence of IRRs (n = 50) were found in patients treated with rituximab (incidence IRR 26%), followed by patients treated with ipilimumab plus nivolumab (IRR incidence 13%), which was mostly attributed to nivolumab (9%). This is higher compared with literature (2.2%-4.0%). In patients treated with trastuzumab plus pertuzumab, 3.8% had an IRR (n = 3 patients; n = 4 IRRs). For the other drugs, no IRRs were reported. CONCLUSION: In this large real-world cohort, we found higher-than-expected numbers of IRRs of patients treated with ipilimumab plus nivolumab. Our research shows that when IRRs are adequately recognized and managed, all patients can safely continue with mAb treatment.


  • Open Access

    The impact of lower household income and distance to hospital on treatment and survival in patients with localized pancreatic adenocarcinoma

    by Nanske C. Biesma, Lois A. Daamen, Marc G. Besselink, Geert A. Cirkel, C.H.J. van Eijck, Bas Groot Koerkamp, Jan Willem B. de Groot, Maartje Los, Judith de Vos-Geelen, Hanneke W. Wilmink, et al.

    IntroductionSocial deprivation, which is exaggerated by lower household income, shortens life expectancy and worsens cancer survival. In pancreatic adenocarcinoma, novel treatment strategies aim to extend survival and centralization of care has increased distance to hospital. The effect of distance to hospital and different treatment regimens on survival stratified by household income remains unexplored.MethodsA nationwide retrospective study using Netherlands Cancer Registry data (2017–2022) included patients with localized pancreatic adenocarcinoma. Patients were categorized into three groups based on household income (lowest, intermediate and highest income) and two distance groups based on median distance to hospital. Multivariable logistic and Cox regression analyses assessed the effect of lower household income and distance on treatment and survival. Kaplan-Meier curves were used for univariable survival analysis.ResultsAmong 5,926 patients, individuals from lower household income received less anti-cancer treatment (44% lowest vs. 63% highest, P<0.001). Living within 14km increased the likelihood of resection (Odds ratio (OR) 1.44, 95%CI 1.28-1.63, P<0.001) and adjuvant chemotherapy (OR 1.29, 95%CI 1.18–1.71, P<0.001). Median survival was 7 months (lowest income), 9 months (intermediate), and 11 months (highest income) (P<0.001). In the multivariable analysis, worse survival in the lowest income group persisted after case-mix adjustment (HR (highest vs lowest): 0.92, 95% CI 0.86-0.98, P<0.001). However, after additional adjustment for treatment differences, survival differences between income groups disappeared (P=0.180).ConclusionLower household income negatively impacts the likelihood of receiving treatment for patients with pancreatic adenocarcinoma. Additionally, distance to hospital is negatively associated with the probability of receiving resection and subsequent treatment.

  • Open Access

    Figure 2 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma

    by Reinhard Dummer, Shibing Deng, Tao Xie, Nuzhat Pathan, Hedieh Saffari, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen J. Gogas, et al.

    PFS and OS for encorafenib plus binimetinib or encorafenib vs. vemurafenib by (A and B) ERBB2 expression level and (C and D) PI3K pathway mutation status. Bini, binimetinib; BM, biomarker; Enco, encorafenib; Vemu, vemurafenib.

  • Open Access

    Figure 1 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma

    by Reinhard Dummer, Shibing Deng, Tao Xie, Nuzhat Pathan, Hedieh Saffari, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen J. Gogas, et al.

    PFS and OS for encorafenib plus binimetinib or encorafenib vs. vemurafenib by (A and B) TMB and (C and D) cytolytic score. E, Volcano plots of univariable gene expression associations with OS in each arm based on z-scored gene expression values. F, Gene-set enrichment analysis of gene expression associations against hallmark gene signatures; signatures with greatest average NES across arms shown. Bini, binimetinib; BM, biomarker; CYT, cytotoxic score; Enco, encorafenib; NES, normalized enrichment scores; Vemu, vemurafenib.

  • Open Access

    Figure 3 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma

    by Reinhard Dummer, Shibing Deng, Tao Xie, Nuzhat Pathan, Hedieh Saffari, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen J. Gogas, et al.

    Characterization of tumor samples to identify candidate molecular subtypes by K-means clustering and distribution of subtypes by biopsy site. A, Heatmap showing K-means cluster and the expression of key marker genes (AXL and MITF) and cell type scores generated by xCell. B, Distribution of K-means subgroups across biopsy sites. C, OS by K-means subgroup and treatment arm. Bini, binimetinib; Vemu, vemurafenib.

  • Open Access

    Table 1 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma

    by Reinhard Dummer, Shibing Deng, Tao Xie, Nuzhat Pathan, Hedieh Saffari, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen J. Gogas, et al.

    Baseline patient characteristics by biomarker status.

  • Open Access

    Figure 4 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma

    by Reinhard Dummer, Shibing Deng, Tao Xie, Nuzhat Pathan, Hedieh Saffari, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen J. Gogas, et al.

    PFS and OS by detection of BRAF V600 alterations in ctDNA at (A and B) baseline and (C and D) on treatment. Only patients with BRAF V600 alteration detections at baseline are shown in C and D. Bini, binimetinib; D, detectable; Enco, encorafenib; ND, nondetectable; Vemu, vemurafenib.

  • Open Access

    Supplementary Data from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma

    by Reinhard Dummer, Shibing Deng, Tao Xie, Nuzhat Pathan, Hedieh Saffari, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen J. Gogas, et al.

  • Open Access

    Data from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma

    by Reinhard Dummer, Shibing Deng, Tao Xie, Nuzhat Pathan, Hedieh Saffari, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen J. Gogas, et al.

    Purpose:Treatment with encorafenib ± binimetinib is associated with improved survival versus vemurafenib in patients with BRAF V600E/K–mutant advanced melanoma. We retrospectively analyzed genomic and transcriptomic data from the phase III COLUMBUS trial to identify molecular correlates of benefit with encorafenib ± binimetinib.Experimental Design:In COLUMBUS, patients with BRAF V600E/K–mutant locally advanced, unresectable, or metastatic melanoma (n = 921) were randomized to receive encorafenib plus binimetinib, encorafenib, or vemurafenib. We used whole-exome sequencing (n = 666), whole-transcriptome sequencing (RNA sequencing; n = 514), and assessment of circulating tumor DNA (ctDNA) at baseline (n = 336) and on treatment (cycle 2 day 1, n = 184) to evaluate biomarker associations with progression-free and overall survival.Results:Survival benefits with encorafenib plus binimetinib versus vemurafenib were greatest in patients with higher tumor mutational burden (TMB) and those with evidence of tumor immune infiltration (i.e., higher cytolytic score, PD-L1 expression, or IFNγ gene signature scores). Clustering of gene expression profiles identified three tumor subgroups, including an “immune” subgroup associated with improved survival. Detection of BRAF V600 alterations in baseline ctDNA was associated with shorter survival; clearance of BRAF V600 alterations at cycle 2 day 1 was associated with improved survival across arms.Conclusions:The greatest benefits of encorafenib plus binimetinib were observed in patients with evidence of high TMB and/or tumor-immune infiltration, suggesting potential immune contributions to efficacy, which were not observed with vemurafenib. BRAF V600 detectability in ctDNA seems to have utility as a marker of prognosis and response in this population.

  • Open Access

    Associations between spatial distribution of immune cell subsets and clinical outcomes in patients with advanced melanoma treated with immune checkpoint inhibitors: results from the PUMA challenge

    by Mark Schuiveling, Hong Liu, Daniel Eek, Martina Hanusová, Isabella A.J. van Duin, Laurens Sebastian ter Maat, Janneke C. van der Weerd, Franchette W.P.J. van Den Berkmortel, Christian U. Blank, Gerben E. Breimer, et al.

    Patients with advanced melanoma are treated with immune checkpoint inhibitors (ICIs), yet less than 50% of patients achieve a durable response while all patients are exposed to the risk of severe side effects. Tumor-infiltrating lymphocytes (TILs) in pathology images are associated with ICI outcomes, but manual assessment is subjective. In addition, the predictive value of other immune cell subsets, including plasma cells, neutrophils, histiocytes, and melanophages, remains unclear. We organized the Panoptic segmentation of nUclei and tissue in advanced MelanomA (PUMA) challenge to evaluate whether the spatial localization of TILs and other immune cell subsets on melanoma H&E slides collected before start of treatment was associated with treatment outcomes. Algorithm performance was evaluated on a hidden test set, after which top-ranked algorithms were applied to pre-treatment metastatic whole-slide images from a large, multicenter cohort of patients with advanced melanoma treated with first-line ICIs ( n =1102). Automatically quantified tissue features and immune cell subsets were then associated with clinical outcomes. Top-performing algorithms improved detection of immune cell subsets, although accuracy for rare classes remained limited. Across challenge participants, TIL density showed the most consistent association with treatment response and survival. Associations for stromal TILs were weaker, while plasma cells, histiocytes, melanophages, neutrophils, necrosis and blood vessels did not show independent associations with outcomes. Overall, the results from the PUMA challenge improved the state of the art of immune cell detection in melanoma histopathology and show that intra-tumoral lymphocytes are the immune cell subset most consistently associated with treatment response and survival. Highlights: We organized the first melanoma-specific tissue and nuclei segmentation competition Winning algorithms were applied to 1102 whole-slide images for biomarker analysis Intra-tumoral TILs were associated with response to immune checkpoint inhibitors Other immune cell subsets showed no independent association with treatment outcomes Tissue segmentation on WSIs was limited by low heterogeneity in training data. Graphical